121 related articles for article (PubMed ID: 31138901)
1. Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment.
Bedoui S; Dallel M; Barbirou M; Stayoussef M; Mokrani A; Mezlini A; Bouhaouala B; Almawi WY; Yacoubi-Loueslati B
Cancer Gene Ther; 2020 May; 27(5):311-318. PubMed ID: 31138901
[TBL] [Abstract][Full Text] [Related]
2. Association of interleukin-17A polymorphisms with the risk of colorectal cancer: A case-control study.
Bedoui SA; Barbirou M; Stayoussef M; Dallel M; Mokrani A; Makni L; Mezlini A; Bouhaouala B; Yacoubi-Loueslati B; Almawi WY
Cytokine; 2018 Oct; 110():18-23. PubMed ID: 29689450
[TBL] [Abstract][Full Text] [Related]
3. Identification of Two Subgroups of FOLFOX Resistance Patterns and Prediction of FOLFOX Response in Colorectal Cancer Patients.
Tian S; Wang F; Lu S; Chen G
Cancer Invest; 2021 Jan; 39(1):62-72. PubMed ID: 33258714
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
5. Utility of Serial Transcriptomic Analyses to Characterize the Resistome and to Refine Treatment Selection for Metastatic Colon Cancer: Case Report.
Castro MP; Afshar M; Williams C; Turcat T; Parker D; Gordon E; Zambelli J; McDonald A; Suh C; Baylon S; Biskup S
Clin Colorectal Cancer; 2021 Mar; 20(1):96-99. PubMed ID: 33353848
[No Abstract] [Full Text] [Related]
6. [Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer].
Muneoka K; Shirai Y; Sasaki M; Sakata J; Kanda J; Wakabayashi H; Wakai T
Gan To Kagaku Ryoho; 2016 Mar; 43(3):323-6. PubMed ID: 27067847
[TBL] [Abstract][Full Text] [Related]
7. Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies.
Fan CW; Chen T; Shang YN; Gu YZ; Zhang SL; Lu R; OuYang SR; Zhou X; Li Y; Meng WT; Hu JK; Lu Y; Sun XF; Bu H; Zhou ZG; Mo XM
Cell Death Dis; 2013 Oct; 4(10):e828. PubMed ID: 24091671
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
Shitara K; Munakata M; Muto O; Kasai M; Okada R; Mitobe S; Sakata Y
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1079-84. PubMed ID: 17637544
[TBL] [Abstract][Full Text] [Related]
9. Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen.
Magagnoli M; Masci G; Carnaghi C; Zucali PA; Castagna L; Morenghi E; Santoro A
Ann Oncol; 2003 Jun; 14(6):959-60. PubMed ID: 12796035
[No Abstract] [Full Text] [Related]
10. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
[TBL] [Abstract][Full Text] [Related]
11. Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX.
Kim MJ; Han SW; Lee DW; Cha Y; Lee KH; Kim TY; Oh DY; Kim SH; Im SA; Bang YJ; Kim TY
Cancer Res Treat; 2016 Jul; 48(3):990-7. PubMed ID: 26790967
[TBL] [Abstract][Full Text] [Related]
12. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.
Goldstein D; Mitchell P; Michael M; Beale P; Friedlander M; Zalcberg J; White S; Clarke S
Br J Cancer; 2005 Mar; 92(5):832-7. PubMed ID: 15756253
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant Systemic Chemotherapy with S-1/Oxaliplatin or mFOLFOX6 after Curative Resection of Distant Metastases in Patients with Colorectal Cancer].
Miyata R; Kameyama N; Tomita M; Mitsuhashi H; Baba S; Amada E
Gan To Kagaku Ryoho; 2016 Mar; 43(3):327-30. PubMed ID: 27067848
[TBL] [Abstract][Full Text] [Related]
14. [A case of locally advanced rectal cancer responding to FOLFOX].
Kume S; Kubota T; Takahashi M; Hashimoto D; Hirata T; Torigoe Y; Ikeda O
Gan To Kagaku Ryoho; 2009 Apr; 36(4):659-61. PubMed ID: 19381043
[TBL] [Abstract][Full Text] [Related]
15. SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.
Kap EJ; Seibold P; Scherer D; Habermann N; Balavarca Y; Jansen L; Zucknick M; Becker N; Hoffmeister M; Ulrich A; Benner A; Ulrich CM; Burwinkel B; Brenner H; Chang-Claude J
Int J Cancer; 2016 Jun; 138(12):2993-3001. PubMed ID: 26835885
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
17. Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.
Chen D; Wen X; Song YS; Rhee YY; Lee TH; Cho NY; Han SW; Kim TY; Kang GH
Clin Epigenetics; 2016; 8():36. PubMed ID: 27051466
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy Alone for Patients With Stage II/III Rectal Cancer Undergoing Radical Surgery.
AlGizawy SM; Essa HH; Ahmed BM
Oncologist; 2015 Jul; 20(7):752-7. PubMed ID: 26040621
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic analysis of 443 cases of stage II colorectal cancer and the value of adjuvant chemotherapy].
Zhou ZG; Pan ZZ; Wan DS; Li LR; Wu XJ; Ding PR; Lin JZ; Peng ZH
Ai Zheng; 2009 Sep; 28(9):908-12. PubMed ID: 19728905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
